rs8111930 — MRPL4 MRPL4 Atopy-Associated Intronic Variant

MRPL4 rs8111930 — A Mitochondrial Regulator in the Allergic Pathway

Most people carry the common G allele at rs8111930 — the majority genotype — yet it is also the allele that marginally tips the immune balance toward atopic sensitisation. This variant sits in an intron of MRPL4¹¹ MRPL4
Mitochondrial Ribosomal Protein L4, a nuclear-encoded component of the 39S large subunit of the mitochondrial ribosome; required for translation of the 13 proteins encoded in mitochondrial DNA, located on chromosome 19p13.2 near the gene for ICAM-1²² ICAM-1
intercellular adhesion molecule-1, a surface protein on endothelial cells and immune cells that mediates cell-cell adhesion during inflammatory responses; soluble ICAM-1 levels are elevated in allergic rhinitis. The minor A allele (~9% globally) is protective against atopy; the common G allele confers modestly elevated risk.

The Mechanism

Although rs8111930 lies within an intron and does not change the MRPL4 protein sequence, in silico transcription factor binding site analysis³³ in silico transcription factor binding site analysis
computational prediction of DNA–protein binding motifs using position weight matrices from known transcription factor binding data shows that the A→G substitution has two consequences: (1) loss of a binding site for AREB6⁴⁴ AREB6
Atp1a1 regulatory element binding factor 6, also known as ZEB1/ZFHEP; a zinc-finger/homeodomain transcription factor that acts as a negative regulator of IL-2 gene transcription after T-cell activation, and is involved in tissue-specific gene expression and early development, and (2) gain of a new binding site for CREB2⁵⁵ CREB2
cAMP-responsive element binding protein 2, also known as ATF4; activates transcription in response to cAMP signalling and cellular stress.

The net result of the G allele is altered regulation of MRPL4 expression in immune tissues. MRPL4 has been identified as a downstream target of HIF-1α⁶⁶ HIF-1α
Hypoxia-Inducible Factor 1-alpha, the master transcriptional regulator of the cellular hypoxic response; in myeloid immune cells, HIF-1α controls inflammatory cytokine production and mast cell activation, and is critical in allergen-induced dendritic cell activation. When HIF-1α signalling is altered, immune cell activation thresholds shift — and in the context of allergen exposure, this can promote atopic sensitisation and allergic rhinitis.

The nearby ICAM-1 locus adds a further mechanistic dimension: soluble ICAM-1 regulates nasal allergic reactions, and genetic variation in this chromosomal region is biologically plausible as an atopy modifier.

The Evidence

The primary evidence comes from a genome-wide association study by Andiappan et al.⁷⁷ Andiappan et al.
Genome-wide association study for atopy and allergic rhinitis in a Singapore Chinese population. PLoS ONE, 2011 that examined 515 atopic cases and 486 controls in a discovery stage, then replicated top findings in a separate cohort of 2,323 atopic cases and 511 controls. rs8111930 in MRPL4 emerged as one of only two SNPs to reach genome-wide significance across both stages: the A allele was associated with 31% reduced odds of atopy (OR=0.69, p=4.46×10⁻⁵ combined) and 38% reduced odds of allergic rhinitis specifically (OR=0.64, p=7.26×10⁻⁵ combined). The consistent direction across discovery and replication phases — with the expected attenuation of effect size between stages (OR 0.50 → 0.78) — is characteristic of a true positive GWAS signal.

Independent support for MRPL4 as an allergic rhinitis susceptibility gene comes from Wei et al.⁸⁸ Wei et al.
The association between polymorphisms in the MRPL4 and TNF-α genes and susceptibility to allergic rhinitis. PLoS ONE, 2013, which enrolled 414 AR patients and 293 healthy controls from a Han Chinese population in Beijing. Although this study examined a second MRPL4 SNP (rs11668618, not rs8111930), it confirmed the gene's relevance to AR susceptibility and independently reinforced the MRPL4– allergic rhinitis link in a distinct population.

The evidence level is moderate: discovery-replication GWAS with two independent populations, a plausible mechanistic pathway via HIF-1α, but limited functional validation and no large multi-ethnic meta-analyses specifically for this variant.

Practical Actions

The GG genotype (carried by ~83% of the global population) confers modest excess atopy risk via altered MRPL4 transcription regulation. The actionable implications are targeted toward allergen sensitisation management rather than molecular pathway manipulation:

Nasal allergen burden reduction: The rs8111930 risk signal is strongest for allergic rhinitis specifically. In people who carry the GG genotype and develop nasal allergy symptoms, systematic allergen reduction (HEPA filtration, dust-mite covers, pollen avoidance during peak seasons) addresses the specific trait this variant is associated with.

Monitoring for progressing atopic disease: GG carriers with early-onset atopic features (eczema in infancy, food allergy) are at marginally elevated risk for the atopic march — progression to allergic rhinitis and asthma. Early allergen identification and immunotherapy evaluation is more evidence-supported when multiple atopy risk alleles are present.

No pharmacological implication currently: There is no established drug target or supplement with documented evidence for MRPL4-pathway modulation at this variant. Actions are limited to allergen monitoring and sensitisation reduction.

Interactions

rs8111930 × rs2303067 (SPINK5): rs2303067 SPINK5 Lys420Glu is the primary SPINK5 skin barrier variant in the GeneOps catalog. The two variants act through independent pathways: SPINK5/LEKTI operates at the epidermal barrier, while MRPL4/HIF-1α operates in immune cell activation. Carriers of risk alleles at both loci may have additive atopy susceptibility — barrier dysfunction (SPINK5) enabling allergen sensitisation combined with reduced immune regulatory capacity (MRPL4) lowering the threshold for a sustained allergic response. No published study has formally tested this combination.